Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
PFIZER | DISHMAN PHARMA | PFIZER/ DISHMAN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 42.4 | 25.1 | 168.8% | View Chart |
P/BV | x | 7.0 | 3.3 | 210.2% | View Chart |
Dividend Yield | % | 0.5 | 0.7 | 73.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-19 |
DISHMAN PHARMA Mar-16 |
PFIZER/ DISHMAN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,840 | 374 | 1,025.6% | |
Low | Rs | 2,080 | 129 | 1,613.7% | |
Sales per share (Unadj.) | Rs | 455.0 | 197.8 | 230.0% | |
Earnings per share (Unadj.) | Rs | 93.8 | 21.2 | 442.2% | |
Cash flow per share (Unadj.) | Rs | 109.4 | 34.7 | 315.0% | |
Dividends per share (Unadj.) | Rs | 22.50 | 2.00 | 1,125.0% | |
Dividend yield (eoy) | % | 0.8 | 0.8 | 95.6% | |
Book value per share (Unadj.) | Rs | 658.2 | 179.9 | 365.9% | |
Shares outstanding (eoy) | m | 45.75 | 80.69 | 56.7% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.5 | 1.3 | 511.4% | |
Avg P/E ratio | x | 31.6 | 11.9 | 266.0% | |
P/CF ratio (eoy) | x | 27.1 | 7.2 | 373.4% | |
Price / Book Value ratio | x | 4.5 | 1.4 | 321.5% | |
Dividend payout | % | 24.0 | 9.4 | 254.4% | |
Avg Mkt Cap | Rs m | 135,420 | 20,306 | 666.9% | |
No. of employees | `000 | 2.6 | 0.8 | 317.4% | |
Total wages/salary | Rs m | 3,238 | 5,355 | 60.5% | |
Avg. sales/employee | Rs Th | 7,911.4 | 19,252.7 | 41.1% | |
Avg. wages/employee | Rs Th | 1,230.9 | 6,459.5 | 19.1% | |
Avg. net profit/employee | Rs Th | 1,630.7 | 2,064.1 | 79.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,815 | 15,961 | 130.4% | |
Other income | Rs m | 1,674 | 265 | 630.7% | |
Total revenues | Rs m | 22,489 | 16,226 | 138.6% | |
Gross profit | Rs m | 5,712 | 4,103 | 139.2% | |
Depreciation | Rs m | 714 | 1,091 | 65.5% | |
Interest | Rs m | 73 | 944 | 7.7% | |
Profit before tax | Rs m | 6,599 | 2,334 | 282.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 1 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,309 | 624 | 370.2% | |
Profit after tax | Rs m | 4,291 | 1,711 | 250.7% | |
Gross profit margin | % | 27.4 | 25.7 | 106.7% | |
Effective tax rate | % | 35.0 | 26.7 | 130.9% | |
Net profit margin | % | 20.6 | 10.7 | 192.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,167 | 11,018 | 246.6% | |
Current liabilities | Rs m | 8,917 | 9,517 | 93.7% | |
Net working cap to sales | % | 87.7 | 9.4 | 932.3% | |
Current ratio | x | 3.0 | 1.2 | 263.2% | |
Inventory Days | Days | 68 | 110 | 61.4% | |
Debtors Days | Days | 30 | 35 | 86.4% | |
Net fixed assets | Rs m | 8,862 | 16,304 | 54.4% | |
Share capital | Rs m | 458 | 161 | 283.5% | |
"Free" reserves | Rs m | 29,656 | 12,907 | 229.8% | |
Net worth | Rs m | 30,113 | 14,516 | 207.5% | |
Long term debt | Rs m | 25 | 4,189 | 0.6% | |
Total assets | Rs m | 39,400 | 29,805 | 132.2% | |
Interest coverage | x | 91.5 | 3.5 | 2,636.8% | |
Debt to equity ratio | x | 0 | 0.3 | 0.3% | |
Sales to assets ratio | x | 0.5 | 0.5 | 98.7% | |
Return on assets | % | 11.1 | 8.9 | 124.3% | |
Return on equity | % | 14.2 | 11.8 | 120.9% | |
Return on capital | % | 22.1 | 17.5 | 126.3% | |
Exports to sales | % | 0 | 24.8 | 0.0% | |
Imports to sales | % | 0 | 3.7 | 0.0% | |
Exports (fob) | Rs m | NA | 3,956 | 0.0% | |
Imports (cif) | Rs m | NA | 596 | 0.0% | |
Fx inflow | Rs m | 428 | 4,952 | 8.6% | |
Fx outflow | Rs m | 786 | 697 | 112.9% | |
Net fx | Rs m | -358 | 4,255 | -8.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 978 | 2,786 | 35.1% | |
From Investments | Rs m | 351 | -1,529 | -23.0% | |
From Financial Activity | Rs m | -1,099 | -941 | 116.7% | |
Net Cashflow | Rs m | 231 | 316 | 72.9% |
Indian Promoters | % | 0.0 | 61.4 | - | |
Foreign collaborators | % | 63.9 | 0.0 | - | |
Indian inst/Mut Fund | % | 7.5 | 3.7 | 202.7% | |
FIIs | % | 4.9 | 12.7 | 38.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 23.7 | 22.1 | 107.2% | |
Shareholders | 85,207 | 46,261 | 184.2% | ||
Pledged promoter(s) holding | % | 0.0 | 35.8 | - |
Compare PFIZER With: STRIDES PHARMA SCIENCE ELDER PHARMA SUVEN LIFE SCIENCES ALEMBIC PHARMA WOCKHARDT
Compare PFIZER With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.
For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
In this video, I'll show you how to get started on the path to daily trading profits.
More